Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2019 Dec 19;40(3):656–669. doi: 10.1161/ATVBAHA.119.313366

Figure 3.

Figure 3.

Retinoic acid suppressed SMC EV TNAP activity. (A) EV TNAP activity from primary human coronary artery SMC treated for two weeks in CM or OM with DMSO vehicle (0.1%) or 1 μmol/L ATRA. (B) SMC EV abundance and (C) diameter from SMC treated for two weeks. Error bars indicate STDEV of mean. ****P < 0.0001 analyzed by ANOVA; n = 9 donors.